Patents by Inventor Osamu Irie

Osamu Irie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8497286
    Abstract: The present invention relates to a compound of the formula I wherein R1, R2, R3, R4 and R5 are as defined in the specification, for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations a compound of that class; a method of treatment comprising administering a compound of that class and a method for its manufacture.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: July 30, 2013
    Assignee: Novartis AG
    Inventors: Fumiaki Yokokawa, Takeru Ehara, Shimpei Kawakami, Osamu Irie, Masaki Suzuki, Yuko Hitomi, Atsushi Toyao
  • Patent number: 8383650
    Abstract: The present invention relates to a compound of the formula I wherein R1, R2, R3, R4 and R5 are as defined in the specification, for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations a compound of that class; a method of treatment comprising administering a compound of that class and a method for its manufacture.
    Type: Grant
    Filed: June 25, 2008
    Date of Patent: February 26, 2013
    Assignee: Novartis AG
    Inventors: Fumiaki Yokokawa, Takeru Ehara, Shimpei Kawakami, Osamu Irie, Masaki Suzuki, Yuko Hitomi, Atsushi Toyao
  • Publication number: 20130005770
    Abstract: The present invention relates to a compound of the formula I wherein R1, R2, R3, R4 and R5 are as defined in the specification, for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations a compound of that class; a method of treatment comprising administering a compound of that class and a method for its manufacture.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 3, 2013
    Inventors: Fumiaki Yokokawa, Takeru Ehara, Shimpei Kawakami, Osamu Irie, Masaki Suzuki, Yuko Hitomi, Atsushi Toyao
  • Patent number: 8129411
    Abstract: The invention relates to 3,5-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5-substituted piperidine compound, and/or a method of treatment comprising administering a 3,5-substituted piperidine compound, a method for the manufacture of a 3,5-substituted piperidine compound, and novel intermediates and partial steps for its synthesis. The compounds have the formula I? wherein R1, R2, T, R3 and R4 are as defined in the specification.
    Type: Grant
    Filed: December 28, 2006
    Date of Patent: March 6, 2012
    Assignee: Novartis AG
    Inventors: Takeru Ehara, Philipp Grosche, Osamu Irie, Yuki Iwaki, Takanori Kanazawa, Shimpei Kawakami, Kazuhide Konishi, Muneto Mogi, Masaki Suzuki, Fumiaki Yokokawa
  • Patent number: 7820818
    Abstract: The invention provides compounds of formula I or a pharmaceutically acceptable salt or ester thereof wherein the symbols have meaning as defined, which are inhibitors of cathepsin K and find use pharmaceutically for treatment of diseases and medical conditions in which cathepsin K is implicated, e.g. various disorders including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis and tumors.
    Type: Grant
    Filed: March 6, 2009
    Date of Patent: October 26, 2010
    Assignee: Novartis AG
    Inventors: Eva Altmann, Claudia Betschart, Kenji Hayakawa, Osamu Irie, Junichi Sakaki, Genji Iwasaki, Rene Lattmann, Martin Missbach, Naoki Teno
  • Patent number: 7807709
    Abstract: The invention relates to the use of (3,4-di-, 3,3,4-tri, 3,4,4-tri- or 3,3,4,4-tetra-)substituted pyrrolidine compounds for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; compounds that are part of a subclass of these substituted pyrrolidine compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; new compounds that are part of a subclass of these substituted pyrrolidine compounds; pharmaceutical formulations comprising said substituted pyrrolidine compounds, and/or a method of treatment comprising administering said substituted pyrrolidine compounds, a method for the manufacture especially of said new substituted pyrrolidine compounds, as well as novel intermediates, starting materials and/or partial steps for their synthesis
    Type: Grant
    Filed: March 21, 2006
    Date of Patent: October 5, 2010
    Assignee: Novartis AG
    Inventors: Claus Ehrhardt, Osamu Irie, Edwige Liliane Lorthiois, Juergen Klaus Maibaum, Nils Ostermann, Holger Sellner
  • Publication number: 20100160305
    Abstract: 3,4,5-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,4,5-substituted piperidine compound, and/or a method of treatment comprising administering a 3,4,5-substituted piperidine compound, a method for the manufacture of a 3,4,5-substituted piperidine compound, and novel intermediates and partial steps for its synthesis. The compounds are of the formula I, wherein the substitutents are as defined in the specification.
    Type: Application
    Filed: March 7, 2006
    Publication date: June 24, 2010
    Applicant: NOVARTIS AG
    Inventors: Keiichi Masuya, Fumiaki Yokokawa, Osamu Irie, Atsuko Nihonyanagi, Takeru Ehara, Kazuhide Konishi, Takanori Kanazawa, Masaki Suzuki
  • Patent number: 7704996
    Abstract: The present invention relates to the use of a 2-cyanopyrimidine compound of the formula wherein R1, R2, R3 and X are as defined in the specification and in the claims, in free form or in salt form, and, where possible, in tautomeric form, as an inhibitor of the activity of cathepsin S.
    Type: Grant
    Filed: August 16, 2005
    Date of Patent: April 27, 2010
    Assignee: Novartis AG
    Inventors: Terance William Hart, Allan Hallett, Fumiaki Yokokawa, Hajime Hirao, Takeru Ehara, Atsuko Iwasaki, Junichi Sakaki, Keiichi Masuya, Masashi Kishida, Osamu Irie
  • Publication number: 20100029647
    Abstract: 3,4(,5)-substituted tetrahydropyridine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,4(,5)-substituted tetrahydropyridine compound, and/or a method of treatment comprising administering a 3,4(,5)-substituted tetrahydropyridine compound, a method for the manufacture of a 3,4(,5)-substituted tetrahydropyridine compound, and novel intermediates and partial steps for its synthesis. The 3,4(,5)-substituted tetrahydropyridine compounds have the formula I wherein the substituents and symbols are as described in the specification.
    Type: Application
    Filed: January 12, 2006
    Publication date: February 4, 2010
    Inventors: Keiichi Masuya, Osamu Irie, Atsuko Nihonyanagi, Atsushi Toyao, Takanori Kanazawa
  • Publication number: 20090227596
    Abstract: The invention provides compounds of formula I or a pharmaceutically acceptable salt or ester thereof wherein the symbols have meaning as defined, which are inhibitors of cathepsin K and find use pharmaceutically for treatment of diseases and medical conditions in which cathepsin K is implicated, e.g. various disorders including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis and tumors.
    Type: Application
    Filed: March 6, 2009
    Publication date: September 10, 2009
    Inventors: Eva Altmann, Claudia Betschart, Kenji Hayakawa, Osamu Irie, Junichi Sakaki, Genji Iwasaki, Rene Lattmann, Martin Missbach, Naoki Teno
  • Publication number: 20090192148
    Abstract: The invention relates to 3,5-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5-substituted piperidine compound, and/or a method of treatment comprising administering a 3,5-substituted piperidine compound, a method for the manufacture of a 3,5-substituted piperidine compound, and novel intermediates and partial steps for its synthesis. The compounds have the formula I? wherein R1, R2, T, R3 and R4 areas defined in the specification.
    Type: Application
    Filed: December 28, 2006
    Publication date: July 30, 2009
    Inventors: Takeru Ehara, Philipp Grosche, Osamu Irie, Yuki Iwaki, Takanori Kanazawa, Shimpei Kawakami, Kazuhide Konishi, Muneto Mogi, Masaki Suzuki, Fumiaki Yokokawa
  • Publication number: 20090186889
    Abstract: The invention provides compounds of formula I or a pharmaceutically acceptable salt or ester thereof formula I wherein the symbols have the meaning as defined in the description. Said compounds are inhibitors of cathepsin K and/or cathepsin S and are useful for the treatment of diseases and medical conditions in which cathepsin K and or cathepsin S is implicated, e.g. various disorders including neuropathic pain, inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis, multiple sclerosis and tumours.
    Type: Application
    Filed: March 30, 2009
    Publication date: July 23, 2009
    Inventors: Osamu Irie, Genji Iwasaki, Keiichi Masuya, Takahiro Miyake, Naoki Teno
  • Patent number: 7544688
    Abstract: The invention provides compounds of Formula (I) or a pharmaceutically acceptable salt or ester thereof wherein the symbols have meaning as defined, which are inhibitors of cathepsin K and find use pharmaceutically for treatment of diseases and medical conditions in which cathepsin K is implicated, e.g. various disorders including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis and tumors.
    Type: Grant
    Filed: August 29, 2003
    Date of Patent: June 9, 2009
    Assignee: Novartis AG
    Inventors: Eva Altmann, Claudia Betschart, Kenji Hayakawa, Osamu Irie, Junichi Sakaki, Genji Iwasaki, Rene Lattmann, Martin Missbach, Naoki Teno
  • Patent number: 7531546
    Abstract: The invention provides compounds of formula (I) or a pharmaceutically acceptable salt or ester thereof formula (I) wherein the symbols have the meaning as defined in the description. Said compounds are inhibitors of cathepsin K and/or cathepsin S and are useful for the treatment of diseases and medical conditions in which cathepsin K and/or cathepsin S is implicated, e.g. various disorders including neuropathic pain, inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis, multiple sclerosis and tumors.
    Type: Grant
    Filed: February 27, 2004
    Date of Patent: May 12, 2009
    Assignee: Novartis AG
    Inventors: Osamu Irie, Genji Iwasaki, Keiichi Masuya, Takahiro Miyake, Naoki Teno
  • Publication number: 20090054467
    Abstract: The invention provides compounds of Formula I or a pharmaceutically acceptable salt or ester thereof wherein the symbols have meaning as defined, which are inhibitors of cathepsin K and find use pharmaceutically for treatment of diseases and medical conditions in which cathepsin K is implicated, e.g. various disorders including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis and tumors.
    Type: Application
    Filed: September 25, 2008
    Publication date: February 26, 2009
    Inventors: Claudia Betschart, Kenji Hayakawa, Osamu Irie, Junichi Sakaki, Genji Iwasaki, Rene Lattmann, Martin Missbach, Naoki Teno
  • Publication number: 20090048230
    Abstract: The present invention relates to the use of a 2-cyanopyrimidine compound of the formula wherein R1, R2, R3 and X are as defined in the specification and in the claims, in free form or in salt form, and, where possible, in tautomeric form, as an inhibitor of the activity of cathepsin S.
    Type: Application
    Filed: August 16, 2005
    Publication date: February 19, 2009
    Inventors: Terance William Hart, Allan Hallett, Fumiaki Yokokawa, Hajime Hirao, Takeru Ehara, Atsuko Iwasaki, Junichi Sakaki, Keiichi Masuya, Masashi Kishida, Osamu Irie
  • Publication number: 20080319018
    Abstract: The present invention relates to a compound of the formula I wherein R1, R2, R3, R4 and R5 are as defined in the specification, for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations a compound of that class; a method of treatment comprising administering a compound of that class and a method for its manufacture.
    Type: Application
    Filed: June 25, 2008
    Publication date: December 25, 2008
    Inventors: Fumiaki Yokokawa, Takeru Ehara, Shimpei Kawakami, Osamu Irie, Masaki Suzuki, Yuku Hitomi, Atsushi Toyao
  • Patent number: 7452886
    Abstract: The invention provides compounds of Formula I or a pharmaceutically acceptable salt or ester thereof wherein the symbols have meaning as defined, which are inhibitors of cathepsin K and find use pharmaceutically for treatment of diseases and medical conditions in which cathepsin K is implicated, e.g. various disorders including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis and tumors.
    Type: Grant
    Filed: August 29, 2002
    Date of Patent: November 18, 2008
    Assignee: Novartis AG
    Inventors: Claudia Betschart, Kenji Hayakawa, Osamu Irie, Junichi Sakaki, Genji Iwasaki, Rene Lattmann, Martin Missbach, Naoki Teno
  • Publication number: 20080194629
    Abstract: The invention relates to 3,5-piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5-piperidine compound, and/or a method of treatment comprising administering a 3,5-piperidine compound, a method for the manufacture of a 3,5-piperidine compound, and novel intermediates and partial steps for their synthesis. Especially, the 3,5-piperidine compounds have the formula I, wherein the symbols have the meanings described in the specification.
    Type: Application
    Filed: May 2, 2006
    Publication date: August 14, 2008
    Inventors: Daniel Kaspar Baeschlin, Werner Breitenstein, Claus Ehrhardt, Juergen Klaus Maibaum, Nils Ostermann, Juerg Zimmermann, Simon Rudisser, Eric Vangrevelinghe, Osamu Irie, Ichiro Umemura, Masaki Suzuki, Muneto Mogi, Takanori Kanazawa, Fumiaki Yokokawa, Atsuko Nihonyanagi
  • Publication number: 20080194549
    Abstract: The invention relates to the use of (3,4-di-, 3,3,4-tri, 3,4,4-tri- or 3,3,4,4-tetra-)substituted pyrrolidine compounds for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; compounds that are part of a subclass of these substituted pyrrolidine compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; new compounds that are part of a subclass of these substituted pyrrolidine compounds; pharmaceutical formulations comprising said substituted pyrrolidine compounds, and/or a method of treatment comprising administering said substituted pyrrolidine compounds, a method for the manufacture especially of said new substituted pyrrolidine compounds, as well as novel intermediates, starting materials and/or partial steps for their synthesis
    Type: Application
    Filed: March 21, 2006
    Publication date: August 14, 2008
    Inventors: Claus Ehrhardt, Osamu Irie, Edwige Liliane Jeanne Lorthiois, Juergen Klaus Maibaum, Nils Ostermann, Holger Sellner